

University of California, San Francisco
CURRICULUM VITAE

Name: Soonmee Cha, MD

Current Position: Professor of Radiology and Neurological Surgery
Program Director, Diagnostic Radiology Residency
Vice Chair for Education
Department of Radiology and Biomedical Imaging
University of California San Francisco

Address: 350 Parnassus Ave, Suite 307, 307H
University of California, San Francisco
San Francisco, CA 94143-0628
Voice: 415-353-8913
Fax: 415-502-2899
Email: soonmee.cha@ucsf.edu

EDUCATION

1983 - 1987	Georgetown University, Washington, DC	B.S.	Chemistry
1987 - 1991	Georgetown University, Washington, DC	M.D.	Medicine
1991 - 1992	Georgetown University Hospital, Washington, DC	Internship	Transitional Internship
1992 - 1996	North Shore University Hospital, Manhasset, NY	Residency	Diagnostic Radiology
1996 - 1998	New York University Medical Center, New York, NY	Fellowship	Neuroradiology

LICENSES, CERTIFICATION

1991	National Board of Medical Examiners
1996	American Board of Radiology
1997	New York State Medical License (#209868)
1998	Certificate of Added Qualification Neuroradiology
1999	California State Medical License (#G85328)

PRINCIPAL POSITIONS HELD

1997 - 1998	New York University Medical Center, New York, NY	Clinical Instructor of Neuroradiology	Department of Radiology
1998 - 1999	New York University School of Medicine, New York, NY	Assistant Professor of Clinical Radiology	Department of Radiology
1999 - 2001	New York University School of Medicine, New York, NY	Assistant Professor of Radiology	Department of Radiology
2001 - 2005	University of California San Francisco	Assistant Professor in Residence	Department of Radiology
2005 - 2011	University of California San Francisco	Associate Professor in Residence	Department of Radiology
2011 - present	University of California San Francisco	Professor in Residence	Department of Radiology

OTHER POSITIONS HELD CONCURRENTLY

2001 - 2005	University of California San Francisco	Assistant Professor in Residence, WOS	Department of Neurological Surgery
2005 - present	University of California San Francisco	Associate Professor in Residence, WOS	Department of Neurological Surgery
2012 - present	University of California San Francisco	Diagnostic Radiology Residency Program Director	Department of Radiology & Biomedical Imaging

HONORS AND AWARDS

1994	RSNA Certificate of Merit Award Feinberg MJ, Cha S, Simon DW. "A Biomechanical Approach to Understanding and Analyzing the Swallowing Response". Scientific exhibit at the Radiological Society of North America, Chicago, IL	Radiological Society of North America
1995	RSNA Certificate of Merit Award Cha S, Simon D, Kalina P, et al. "CT, MR and Angiographic Appearance of Unusual Posterior Fossa Lesions". Scientific exhibit at the Radiological Society of North America, Chicago, IL	Radiological Society of North America
2000	ASNR Outstanding Presentation Award in General Neuroradiology at the 38th Annual Meeting in Atlanta, GA, April 2000. Cha S, Pierce S, Knopp EA, et al. "Dynamic Contrast-Enhanced T2*-Weighted Echo-Planar MR Imaging of Tumefactive Demyelinating Lesions"	American Society of Neuroradiology

2001	ASNR Foundation Scholar Award in Neuroradiology Research for 2001. Cha S. "Dynamic Contrast-enhanced T2*-weighted MRI and Histopathological Assessment of Experimental Gliomas".	American Society of Neuroradiology
2006	Best Speaker Award, fMRI/DTI/PWI Morning Categorical Course, International Society of Magnetic Resonance in Medicine, Seattle, WA.	International Society of Magnetic Resonance in Medicine
2010	Hideyo Minagi Outstanding Teacher Award, Department of Radiology and Biomedical Imaging	University of California, San Francisco
2010	Hideyo Minagi Outstanding Teacher Award (June 2010)	
2013	Hideyo Minagi Outstanding Teacher Award, Department of Radiology and Biomedical Imaging	University of California, San Francisco
2013	Starkey J, Cha S. Brain Tumor Mimics, Educational Exhibit - Cum Laude Award	Radiological Society of North America
2013	Hideyo Minagi Outstanding Teacher Award (June 2013)	
2014	Excellence and Innovation in Graduate Medical Education Award	University of California, San Francisco
2014	UCSF Radiology Team - first place win in Phillips Vydareny Imaging Interpretation Competition	Association of University Radiologist
2014	Ranked #1 Diagnostic Radiology Residency Program in the country	Doximity and U.S. News & World Report
2014	Li,Y, Ali,S, Clarke,J, Cha,S, Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Complications, Educational Exhibit - Cum Laude Award	Radiological Society of North America
2014	Excellence and Innovation in Graduate Medical Education Award, University of California San Francisco	

KEYWORDS/AREAS OF INTEREST

Brain tumor, brain cancer, glioblastoma multiforme, gliomas, primary cerebral lymphoma, angiogenesis, hypoxia, invasion, perfusion MR imaging, diffusion-weighted imaging, molecular imaging, biomarkers, microarray, genomics, neural stem cell

CLINICAL ACTIVITIES SUMMARY

I am a board certified radiologist with a certification of added qualification and a two-year fellowship training in neuroradiology. I provide consistently outstanding patient care through expertise in the performance and interpretation of imaging studies of the brain, neck, and spine including the careful use of computed tomography (CT), magnetic resonance imaging (MRI),

and x-ray radiography. I also perform a variety of neuroradiologic procedures such as fluoroscopy or CT-guided lumbar puncture, myelogram, and CT-guided biopsy or aspiration. With early, accurate imaging diagnosis, I am committed to helping patients achieve the best outcomes in brain tumor, stroke, epilepsy, multiple sclerosis, neurodegenerative disease, headache, vasculopathy, infection, and many other neurologic disease. I have a deep clinical and research interest in imaging of brain tumors and I have been the imaging director of brain tumor board at UCSF since 2002.

On a weekly basis I provide clinical services to clinical colleagues in Neurosurgery, Neurology, Neuro-Oncology, Neuropathology, and Radiation Oncology in over 6 hours of interdisciplinary conferences. I attend the brain tumor board at UCSF, which takes place every Thursday and starts at 12:30pm and can last up to 4hrs. I provide imaging interpretation of 30 - 40 brain or spine imaging studies during tumor board. I attend weekly Neuroradiology working conference and multidisciplinary Neuroimaging conference on Thursdays from 8am-10am. I also provide 4-6hrs of neuroimaging consult services in clinical interpretations to our clinical colleagues every week.

MEMBERSHIPS

- 1997 - present Radiological Society of North America
- 1997 - present American Society of Neuroradiology (ASNR)
- 2005 - present International Society of Magnetic Resonance in Medicine (ISMRM)
- 2012 - present Association of Program Directors in Radiology (APDR)

SERVICE TO PROFESSIONAL ORGANIZATIONS

- | | | |
|----------------|---|---|
| 2004 - present | American Society of Neuroradiology | Research Committee Member |
| 2009 - 2012 | International Society of Magnetic Resonance in Medicine | Annual Meeting Program Committee Member |
| 2013 - 2013 | Radiological Society of North America | Annual Meeting Neuroradiology Series: Brain Tumors- Moderator |
| 2014 - 2014 | Radiological Society of North America | Annual Meeting Neuroradiology (Neuro-Oncology) Moderator |

SERVICE TO PROFESSIONAL PUBLICATIONS

- 1998 - present American Journal of Neuroradiology, Reviewer
- 1998 - present Journal of Magnetic Resonance Imaging, Ad Hoc Reviewer
- 2003 - present Cancer Journal, Ad Hoc Reviewer
- 2003 - present Neurology, Ad Hoc Reviewer
- 2005 - 2014 Select Reviews in Neuro-Oncology, Editorial Board Member
- 2006 - present Radiology, Ad Hoc Reviewer
- 2006 - 2014 American Journal of Neuroradiology, Editorial Board Member

INVITED PRESENTATIONS - INTERNATIONAL

- 2002 White matter disease of the brain. - Keynote Lecture, 4th Chinese National Magnetic Resonance Scientific Meeting, Tianjin, People's Republic of China
- 2002 Perfusion MR imaging of intracranial mass lesions - Keynote Lecture, 4th Chinese National Magnetic Resonance Scientific Meeting. Tianjin, People's Republic of China
- 2002 MR Perfusion Techniques. Second International Symposium on CT/MR Perfusion Imaging. San Francisco, California
- 2004 Perfusion MR imaging of brain tumors: Correlation with spectroscopy International Conference on Xenon CT CBF and Related CBF Techniques. Bordeaux, France
- 2005 Update on brain tumor imaging: what neurosurgeons need to know. Neurosurgery Grand Rounds, Seoul National University School of Medicine. Seoul, South Korea
- 2005 Perfusion MR imaging of Brain Tumors, Techniques of Perfusion MR imaging the brain. Third International Symposium on Perfusion Imaging, Chicago, IL
- 2007 Sunday Educational Symposium and Morning Categorical Course (fMRI/DTI/PWI) Lecturer, Annual Meeting of the Internal Society of Magnetic Resonance Medicine, Berlin, Germany
- 2008 Advanced MR Imaging Methods of the Brain. 12th Asian Oceanian Congress of Radiology. Seoul, South Korea
- 2013 State-of-the-Art: Glioma Imaging. XV World Federation of Neurosurgical Societies. Seoul, South Korea
- 2014 Young Professionals Programming: Advances in Imaging: How to Incorporate Them Into Your Practice - Perfusion MRI (Latest Update on Tumor Pre and Post Therapy). The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada
- 2014 Blood Brain Barrier Imaging: Key Concepts When Evaluating Primary Brain Tumors. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada

INVITED PRESENTATIONS - NATIONAL

- 1999 Evaluation of an infarction by MRI & CT. Radiology Update 1999, St. John Hospital and Medical Center. Detroit, Michigan
- 2000 Clinical applications of advanced neuroimaging. Grand Rounds at Broward General Medical Center, Fort Lauderdale, Florida
- 2001 Perfusion MR imaging of intracranial mass lesions. Radiology Grand Rounds, Northwestern University Medical Center, Chicago, Illinois
- 2000 Clinical applications of advanced neuroimaging. Grand Rounds at Broward General Medical Center. Fort Lauderdale, Florida
- 2001 T2*-weighted cerebral perfusion of gliomas. Neuroradiology Education and Research Symposium. American Society of Neuroradiology (ASNR) 39th Annual Meeting, Boston, Massachusetts

- 2003 Perfusion MR Imaging of Brain Tumors and Intracranial Mass Lesions. Radiology Grand Rounds Lecture, Massachusetts General Hospital & Brigham and Women Hospital, Boston, MA
- 2003 Perfusion MR Imaging: Basic Principles and Clinical Applications. Annual Meeting of the American Roentgen Ray Society. San Diego, California
- 2003 Brain tumor imaging with special focus in meningiomas - Keynote lecture. Meningioma Support Group Meeting, San Francisco, California
- 2003 Advances in neuroimaging - Keynote lecture, Sami Disharoon Brain Tumor Research Foundation, San Francisco, California
- 2004 Advances in brain tumor imaging, American Roentgen Ray Society Annual Meeting, Miami, Florida
- 2004 Anatomic and Functional Imaging in the Planning of Conformal Radiation Therapy. ASNR Neuradiology Education and Research Symposium 2004. Seattle, Washington
- 2004 Perfusion MR imaging of pediatric brain tumors. ASNR 42nd Annual Meeting, Seattle, Washington
- 2004 Surrogate biomarkers of glioma by quantitative MR imaging. American Association of Neurological Surgeons and Congress of Neurological Surgeons Section on Tumors Sixth Biennial Satellite Symposium. San Francisco, California
- 2004 Update on Brain Tumor Imaging. First Annual Cancer Symposium, Hackensack Medical Center, Hackensack, New Jersey
- 2004 Perfusion and spectroscopic imaging of brain tumors. American Association of Neurological Surgeons and Congress of Neurological Surgeons Joint Section on Pediatric Neurological Surgery Annual Meeting. San Francisco, California
- 2005 Update on Brain Tumor Imaging: What the Neurosurgeons need to know. Annual Meeting of the American Association of Neurological Surgeons, New Orleans, LA
- 2005 Perfusion MR imaging of the Brain. Annual Meeting of the Internal Society of Magnetic Resonance Medicine, Miami, FL
- 2006 Update on Brain Tumor Imaging: From Anatomy to Physiology. American Society of Neuroradiology, San Diego, CA
- 2006 Morning Categorical Course (fMRI/DTI/PWI) Organizer & Lecturer. Annual Meeting of the Internal Society of Magnetic Resonance Medicine, Seattle, WA
- 2007 Advanced Brain MRI Methods. Irvin I. Kricheff Lecture, New York University School of Medicine, New York, New York
- 2009 Effects of treatment on brain tumors: Postoperative imaging. Annual Meeting of the Radiological Society of North America. Chicago, Illinois
- 2009 Clinical Needs for Quantitative Imaging in Brain Disorders: Brain Tumor Imaging Annual Meeting of the Radiological Society of North America, Chicago, Illinois
- 2009 Clinical Application of Diffusion-weighted Imaging in the Brain, Annual Meeting of the American Society of Neuroradiology, Vancouver, British Columbia, Canada

- 2010 "Imaging of Primary Brain Tumors in Adults" May 15, 2010; American Society of Neuroradiology Symposium, Boston, MA
- 2011 State-of-the-Art Review of Imaging Techniques for Differentiating Recurrent Tumor from Post-treatment Changes in Treated Gliomas. American Society of Radiation Oncology
- 2011 MR Spectroscopy: Histologic-Spectroscopic Correlation. American Society of Radiation Oncology
- 2012 Building a Research Program. Young Physician Programming: Academic Session. American Society of Neuroradiology
- 2012 Super Resolution Track Density Imaging of White Matter Signal Abnormality in Suspected Recurrent High Grade Glioma. Cohen BA, Barajas RF, Yu JPJ, von Morze C, Hess CP, Cha S. Presented at the annual meeting of American Society of Neuroradiology Received ASNR Trainee Award (Cohen BA)
- 2013 State-of-the-Art Review of Imaging Techniques for brain tumors. Cancer Imaging and Radiation Therapy Symposium. Association of Radiation Oncology
- 2013 Imaging Mimics of Common Malignancies - Brain Tumor Mimics. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013, Chicago IL
- 2014 Latest Advances in Brain Tumor Imaging. Radiology Grand Rounds. University of California Davis
- 2014 Brain Tumor Imaging-from Structure to Individual Biology. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, November 30 - December 5, 2014, Chicago IL

INVITED PRESENTATIONS - REGIONAL AND OTHER INVITED PRESENTATIONS

- 2003 Advances in Neuroimaging: Perfusion, Diffusion, and Spectroscopic MR Imaging. San Francisco Neurological Society Annual Meeting, Berkeley, California
- 2003 Perfusion MR Imaging. In-service for MRI technologists, UCSF
- 2003 Introduction to Perfusion MR Imaging. Grand Rounds Lecture, USCF
- 2004 Advances in brain tumor imaging. Key note speaker San Francisco Neurological Society meeting, San Francisco, California
- 2005 Update on brain tumor imaging. Core curriculum series for residents, UCSF
- 2005 Basics of proton MR spectroscopic imaging. In-service for MRI technologists, UCSF
- 2009 Current state of brain tumor imaging. FAIR Seminar, UCSF

CONTINUING EDUCATION AND PROFESSIONAL DEVELOPMENT ACTIVITIES

- 2005 Annual Meetings of American Society of Neuroradiology & International Society of Magnetic Resonance in Medicine & Radiological Society of North America

2006	Annual Meetings of American Society of Neuroradiology & International Society of Magnetic Resonance in Medicine
2007	Annual Meetings of American Society of Neuroradiology & International Society of Magnetic Resonance in Medicine
2008	Annual Meetings of American Society of Neuroradiology & International Society of Magnetic Resonance in Medicine
2009	Annual Meetings of American Society of Neuroradiology & Radiological Society of North America
2010	Annual Meetings of American Society of Neuroradiology & Radiological Society of North America
2010	UCSF CME Course RAD10034 Brain, Body and Breast Imaging in Bermuda
2010	UCSF CME Course RAD10027 Spring Training for Radiologists
2011	Annual Meetings of American Society of Neuroradiology & Radiological Society of North America
2011	UCSF CME Course RAD11019 Imaging and Intervention on the Mayan Riviera
2012	Annual Meetings of American Society of Neuroradiology & Radiological Society of North America
2012	UCSF CME Course RAD13005 Advances in Neuroimaging: Essentials and Cutting-Edge
2012	UCSF CME Course RAD120022 Current Concepts in Neuro and Musculoskeletal Imaging
2012	UCSF CME Course MRO12001 Radiation Oncology Update: Combined Therapies, Combined Images, Combined Vision
2013	Annual Meeting of American Society of Neuroradiology
2013	Annual Meeting of the Radiological Society of North America

GOVERNMENT AND OTHER PROFESSIONAL SERVICE

2005 - present	National Institute of Health	Study Section Member
2005 - present	NIH Study Section: Biomedical Imaging and Technology-A (BMIT-A): Behrouz Shabestari, PhD, National Institute of Health Permanent member	Scientific Review Officer (SRO)
2005 - present	NIH Study Section: ZRG1 SBIB, Ad hoc reviewer, National Institute of Health	NIH study section grant reviewer
2006 - present	American Society of Neuroradiology	Grant Reviews and Research Committee Member

SERVICE ACTIVITIES SUMMARY

I have been a member of NIH study section since 2005. On average I review grants 3 times a year, 10 grants per session. Each grant review entails about 24hrs of careful review and assessment of the impact of the proposal. In addition I am an Ad Hoc reviewer for specialized grant review sessions which come about once a year and I review about 10 grants for these sessions. During the past 9 years of my service, I have enjoyed and taken serious responsibility in being a part of important institution that decides the merits of medical science research proposal and the likelihood of federal funding of a particular research project. Through this process, I have learned a great deal in assessing potential clinical impact of medical research projects and in becoming a better reviewer of others as well as my own research proposal.

I joined the Committee on Human Research at UCSF in April of 2010 to serve and to learn more about the process of getting institutional approval on human research. I served on the committee for 2 years and 5 months, until September 2012, at which time I was asked by my department Chairman to focus on my new role and responsibilities as the Diagnostic Radiology Residency Program Director. During my committee service I attended 2 monthly CHR meetings at Laurel Heights and reviewed anywhere between 8-12 applications per meeting. Each application entailed about 12hrs or my review time. As a committee member I underwent training on the subject of the responsible conduct of research and the procedures on human subject protections. This in-depth training has strengthened my understanding of shared values for the responsible conduct of research that bind all researcher together, such as honesty, accuracy, efficiency, and objectivity. Although this committee required a great deal of time commitment, I learned so much and being a member has given me a renewed conviction in taking serious responsibility in reviewing research proposals as they pertain to the wellness and safety of the subjects involved as well as to the advancement of science.

Since 2005, I have been a member of faculty search committees for the Departments of Radiology, Neurological Surgery, and Radiation Oncology. During this time, I have interviewed over 15 candidates and selected 4 junior faculties in residence series (Jean Nakamura and Igor Barani in the Department of Radiation Oncology; Jennifer Clarke in the Department of Neurological Surgery; and Leo Sugrue in the Department of Radiology). The interview and selection process provided me a great opportunity to meet junior faculty candidates and share their new research ideas and academic aspirations. I am currently informal mentors and senior colleagues to Drs. Clarke and Barani as we collaborate on several research projects on imaging of brain tumor patients treated at UCSF.

I became the Diagnostic Radiology Program Director in July 2012. With changes in board examination structure in 2013 and the ACGME Milestones Project, I have had the unique opportunity to impact the future of our residency program. The ACGME Milestones project is an outcomes-based method of evaluating resident performance within the 6 general competency domains to be demonstrated by residents at particular points during their education. In my role as Diagnostic Radiology Residency Program Director I formed 2 committees -- Clinical Competency Committee and the Program Evaluation Committee -- in compliance with the ACGME Milestones Project. The Clinical Competency Committee meets 4 times a year to evaluate resident performance and each 2 hour meeting requires 10-12 hours of preparation. The Program Evaluation Committee meets twice a year and each 1 hour meeting requires 5-6 hours of preparation. In addition we submit Milestones Reporting to the ACGME twice a year and it takes several days of preparation to complete this. I allocate over 10 hours a week to my program director duties which include meeting with each of our 55 residents 2-4 times a year, advocating to continually improve resident education, collaborating

with faculty and residents to implement new teaching tools and promote an interactive learning environment to achieve responsible teaching and learning.

UCSF CAMPUSWIDE

2010 - 2012	Committee on Human Research, Laurel Heights Committee	Grant proposal reviewer
-------------	---	-------------------------

DEPARTMENTAL SERVICE

2004 - 2004	Biostatistician Search Committee: Interviewing and selecting candidates for departmental biostatistician, Radiology	
2005 - 2005	Computer Support Committee: Attending monthly meeting to discuss issues related to computer support for researchers and academic computing, Radiology	
2005 - present	Radiation Oncology Faculty Search Committee: Interviewing and selecting candidates, Radiation Oncology	
2006 - 2008	Seminar Committee: Attending monthly meeting to discuss relevant topics and speakers for special lectures: FAIR, Grand Rounds, Progress in Radiology, Radiology	
2006 - present	Neuro-oncology Fellow Search Committee: Interviewing and selecting candidates, Neurological Surgery	
2007 - present	Neuro-oncology Faculty Search Committee: Interviewing and selecting candidates, Neurological Surgery	
2012 - present	Executive Committee, Radiology	
2013 - present	Clinical Competency Committee: Evaluation of resident performance semi-annually and ACGME Milestones reporting, Radiology	
2013 - present	Program Evaluation Committee: Diagnostic Radiology program evaluation.	Chair
2014 - present	Neuroradiology Search Committee: Interviewing and selecting candidates, Radiology	

COMMUNITY AND PUBLIC SERVICE

2002 - present	Provide pro-bono consultations for physicians around the country treating patients with brain tumor and tumor mimicking lesions
2004 - present	Provide regular consultations and lectures to a variety of brain tumor support groups (ex. Meningioma Support Group and the Sami Disharoon Brain Tumor Research Foundation)

TEACHING SUMMARY

I believe teaching is an important part of my responsibility as an academic radiologist. I thoroughly enjoy teaching medical students, residents, and fellows as well as clinicians from other discipline. Radiology is taught to the medical students, residents, and fellows both in the

Department of Radiology and from other services, mainly by informal contact in consultation, ward rounds, seminars, demonstrations, etc. Any patient contact is simultaneously a teaching demonstration. During my clinical service days I spend on average 6hrs of my shift providing in depth one-on-one teaching with the trainees scheduled in the reading room with me. In addition I attend the Neuroradiology multidisciplinary conferences which occur every Thursday from 8-10am.

Teaching Neuroradiology to clinicians and trainees from other disciplines of medicine provides me with a greater opportunity to understand the clinical needs and relevance of imaging in the context of making impact in management of patients. In 2010 and 2013 I was nominated and awarded the Department of Radiology Hideyo Minagi Outstanding Teacher Award. The recipient is nominated and selected by the diagnostic radiology residents for outstanding teaching in a given year. I am the first faculty member in the Department of Radiology to have received this award twice. In addition I was nominated and awarded one of the 2014 UCSF Excellence and Innovation in Graduate Medical Education Awards. The award recognizes program coordinators and other staff, faculty, and residents and fellows who show exemplary efforts in improving graduate medical education at UCSF. It is awarded to individuals who have demonstrated a commitment to advancing graduate medical education through educational and clinical quality improvement, service excellence, and innovation.

Since becoming the program director of diagnostic radiology residency in July 2012, I have implemented innovative curriculum and training approaches, which impact quality of resident education. I have developed and implemented new and innovative online curriculum and learning modules for resident education, contributed to an exceptionally supportive, self-directed, accountable, and team-oriented learning environment and made special efforts to recognize excellence in individual residents. With changes in board examination structure in diagnostic radiology in 2013, I took advantage of opportunities to improve resident learning environment and training strategy to better serve our residents' educational needs and encourage faculty to adapt and provide updated teaching material to our residents. All 26 residents who have taken the new board examination have passed with high marks. Our residency program was ranked number one in the country by Doximity and U.S. News & Health Report in September 2014. Doximity is the largest online professional network for U.S. physicians. Doximity provides a Residency Navigator tool to help medical students make informed residency decisions and to increase transparency in the residency match process. Residency ranking reflects peer nominations from physicians who have trained and are board-certified in the respective specialties.

FORMAL TEACHING

Not UCSF	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2002 - 2002	Clinical Magnetic Resonance Imaging, SF, CA	Formal Lecture	Medicine	
	2002 - 2002	CT/MR Perfusion Imaging, SF, CA	Formal Lecture	Medicine	
	2003 - 2003	Solving Problems in Diagnostic Radiology, US Virgin Islands	Formal Lecture	Medicine	

Not UCSF	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2003 - 2003	Solving Problems in Diagnostic Radiology, Kona, Hawaii	Formal Lecture	Medicine	
	2003 - 2003	Diagnostic Radiology Seminars, Maui, Hawaii	Formal Lecture	Medicine	
	2004 - 2004	Current concepts in Neuroimaging, Kona, Hawaii	Formal Lecture	Medicine	
	2004 - 2004	Radiology Spring Training, Tucson, Arizona	Formal Lecture	Medicine	
	2005 - 2005	Diagnostic Radiology, Sonoma, CA	Formal Lecture	Medicine	
	2006 - 2006	Neuro/Musculoskeletal Imaging, Kona, Hawaii	Formal Lecture	Medicine	
	2006 - 2006	Diagnostic Radiology, Kona, Hawaii	Formal Lecture	Medicine	
	2007 - 2007	Neurosurgery Update Two-Thousand-Seven in the Wine Country, Napa, CA	Formal Lecture	Medicine	
	2007 - 2007	Advances in Clinical MR/CT Imaging, San Francisco, CA	Formal Lecture	Medicine	
	2010 - 2010	Spring Training for Radiologists, Orlando, CA	Formal Lecture	Medicine	
	2002 - 2010	Advances in Clinical MR/CT Imaging, San Francisco, CA	Formal Lecture	Medicine	
	2010 - 2010	Neuroradiological and Musculoskeletal Imaging in Monterey, CA	Formal Lecture	Medicine	

Not UCSF	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2010 - 2010	Brain, Body and Breast Imaging in Bermuda, Southampton, Bermuda	Formal Lecture	Medicine	
	2011 - 2011	Imaging and Intervention, Mayakoba, Mexico (4 Lectures)	Formal Lecture	Medicine	
	2011 - 2011	UCSF Annual Review, Comprehensive Clinical Imaging, San Francisco, CA (1 Lecture)	Formal Lecture	Medicine	
	2012 - 2012	Neuro-MSK UCSF CME Course, Co-Chair (Feb2012, Kona, HI)	Formal Lecture	Medicine	
	2012 - 2012	Neuroradiology UCSF CME Course, Co-Chair (September 2012, San Francisco, CA)	Formal Lecture	Medicine	
	2012 - 2012	Brain Tumor Mimics (Course #RCA318A) RSNA Refresher Course 11/27/2012	Formal Lecture	Medicine	
	2012 - 2012	Advances in Structural and High-Field-Strength Imaging (Course# RC718A) RSNA Refresher Course 11/29/2012	Formal Lecture	Medicine	
	2011 - 2014	Annual UCSF Radiology Highlights, San Francisco, CA	Formal Lecture	Medicine	

Not UCSF	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2002 - 2013	Annual Diagnostic Radiology Postgraduate Course, SF, CA	Formal Lecture	Medicine	
	2005 - 2014	Annual Resident Review Course, San Francisco, CA	Formal Lecture	Medicine	

MENTORING SUMMARY

I have been a primary mentor to more than 20 medical and graduate students and over the past decade. I take my mentoring role seriously and make a point to meet with my mentees on a regular basis, on average 2-3 time a month, to provide guidance and career advice. I have also formally mentored 4 junior faculty through my department's faculty mentoring program. In this role I meet with my junior faculty mentees every other month for about an hour to provide guidance and career advice. Mentoring is critical in identifying highly motivated and talented medical trainee who may become the next leaders of their field. Mentoring is a professional activity, a trusted relationship, and a meaningful commitment. As a mentor, I have learned to become a better educator, advocate, academic, and leader. I recognize that professional development through mentorship can be highly beneficial to both mentor and mentee and mentoring is a critical element in preparing future leaders of our profession.

PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program or School	Mentor Type	Role	Current Position
2002 - 2004	Annette Chan	U.C. San Francisco/U. C. Berkeley Graduate Student, Department of Bioengineering		Dissertation Committee Member	Working in Industry
2003 - 2006	Forrest Crawford	U.C. San Francisco Research Associate		Research Supervision	Graduate Student

Dates	Name	Program or School	Mentor Type	Role	Current Position
2003 - 2006	Janine Lupo	U.C. San Francisco/U. C. Berkeley Graduate Student, Department of Bioengineering		Dissertation Committee Member, Research Advisor	Assistant Researcher in the Professional Series, UCSF, Department of Radiology
2004 - 2005	Peter Jun	Medical Student at Stanford University School of Medicine		Mentor and research advisor	4th year Radiology resident, UCSF
2004 - 2007	Joseph Osorio	U.C. San Francisco/U. C. Berkeley Graduate Student, Department of Bioengineering		Dissertation Committee Member	2nd year medical student at UCSF School of Medicine
2006 - 2008	Mathew Zierhut	U.C. San Francisco/U. C. Berkeley Graduate Student, Department of Bioengineering		Dissertation Committee Member, Research Advisor	Working in Industry
2006 - 2010	Il Woo Park	U.C. San Francisco/U. C. Berkeley Graduate Student, Department of Bioengineering		Dissertation Committee Member, Research Advisor	3rd year Bioengineering Graduate Student

Dates	Name	Program or School	Mentor Type	Role	Current Position
2007 - 2009	Ramon Barajas	UCSF Medical Student, Doris Duke Scholar		Mentor of Doris Duke Scholarship and Research Supervisor	Radiology residency at UCSF
2010 - 2010	Francisco Valles	UCSF Medical Student, PACCTR Fellow		Mentor of Pathways to Careers in Clinical and Translational Research (PACCTR) Program and Research Supervisor	PACCTR Fellow

POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2002 - 2004	Joonmi Oh, PhD	Post-Doctoral Researcher		Research Supervision	Scientist at Synarc Company
2003 - 2004	Donna Hoghooghi, MD	Clinical Fellow		Mentor and Research Supervision	Radiology attending at Marin General Hospital
2003 - 2004	Joseph Hoxworth, MD	Radiology Resident		Research Supervision	Neuroradiology Faculty at Mayo Clinic, Phoenix, Arizona
2003 - 2004	Justin Smith, MD, PhD	Neurosurgery Resident		Research Supervision	Neurosurgery Faculty at University of Virginia
2003 - 2005	Lucie Yang, MD, PhD	UCSF Medical Student		Mentor and Research Supervisor	Scientist at Food and Drug Administration

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2003 - 2005	Ashley Aiken, MD	Radiology Resident		Research Supervision	Neuroradiology Faculty at Emory University Medical Center
2003 - 2010	Yan Li, PhD	U.C. San Francisco/U. C. Berkeley Graduate Student		Dissertation Committee Member, Research Advisor	Postdoctoral Fellow at Nelson Lab, UCSF
2006 - 2010	Inas Khayal, PhD	Post-Doctoral Researcher		Dissertation Committee Member, Research Advisor	Searching for an academic career job
2009 - present	Ramon Barajas, MD	Neuroradiology Fellow		Mentor and Research Advisor	Neuroradiology Fellow
2009 - present	John-Paul (JP) Yu, MD, PhD	Neuroradiology Fellow		Mentor and Research Advisor	Neuroradiology Fellow

FACULTY MENTORING

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2008 - 2010	Alison Meadows, MD, PhD	Radiology and Pediatric Cardiology Faculty (Assistant Professor of Clinical Radiology)		Mentor	Attending Physician at Kaiser, San Francisco
2009 - 2010	Natasha Brasic, MD	Radiology Faculty (Assistant Professor in Residence)		Mentor	Associate Professor
2009 - 2012	Jane Wang, MD	Radiology Faculty (Assistant Professor in Residence)		Mentor	Assistant Professor

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2010 - present	Karen Ordovas, MD	Radiology Faculty (Assistant Professor in Residence)		Mentor	Associate Professor

RESEARCH AND CREATIVE ACTIVITIES SUMMARY

I am committed to a career dedicated to patient-oriented research in the field of brain tumor imaging. I believe non-invasive imaging technology will make important contributions to the health of patients through improving the specificity and precision of diagnosis and treatment monitoring, which will in turn have significant impact on therapeutic decisions. With the explosion of knowledge in molecular and cellular biology and genetics of brain tumors, effective and tailored therapy for patients with malignant glioma is on the horizon. Neuroradiologic imaging techniques are also improving at a rapid pace, and in many instances, serve now as a surrogate biomarker for alterations in molecular and cellular biology. We are in the early stages of the capability of *in vivo* molecular profiling of brain tumors at UCSF, which will permit better classification and stratification of tumor biology.

My short-term research goal is to 1) to investigate imaging based classification of primary CNS lymphoma with biologic and clinical relevance and 2) to identify correlative cerebrospinal fluid and tissue markers of clinical prognosis in patients with primary CNS lymphoma.

The main focus of my current research is to identify reliable surrogate markers of prognosis and therapeutic efficacy by quantitative MR imaging methods in patients with brain tumor. Progress in the basic understanding of molecular and genetic aspects of brain tumor is providing new targets for therapies and more rational ways of delivering these novel therapies. Nonetheless, the assessment of therapeutic efficacy remains problematic. My conviction is that by using MR imaging techniques such as perfusion MR imaging, diffusion-weighted imaging, and 3-dimensional proton (^1H) magnetic resonance spectroscopic imaging, detection of changes in tumor angiogenesis, cellularity, invasion, tumor hypoxia, and metabolic burden can be accurately measured and will provide more specific information about a patient's early response to therapy in the context of tumor growth.

The central hypothesis underlying my career development award proposal (K23 funded by the National Institute of Neurological Disease and Stroke) was that the biologic behavior and early stages of an aggressive growth phase in primary brain tumors are related to angiogenesis and cellular proliferation. The goals of the proposed study were to use MR imaging and proton (^1H) MR spectroscopy to characterize tumor malignancy; to correlate MRI-derived relative cerebral blood volume and vascular permeability with histologic vessel density and tumor-related vascular permeability factor expression; and to predict response to treatment following irradiation and chemotherapy in a well-characterized cohort of patients who have a primary glial neoplasm. The results of this study did show that noninvasive MR imaging can provide valuable quantitative information on glioma biology that is predictive of clinical prognosis and biological course of the disease. Based on the preliminary results from this study, I submitted an RO1 application to the NIH that focuses specifically on imaging based classification of glioblastomas that can predict cellular origin, biologic behavior, and clinical prognosis. Currently I am funded by the North American Gamma Knife Consortium grant to study neuroimaging changes in patients with brain metastases treated with radiosurgery or whole-brain radiotherapy. I am also funded by NIH SPORE grant studying low grade gliomas and NIH P01 grant studying high grade gliomas since July 2013.

RESEARCH AWARDS - CURRENT

1. 2P01CA118816-06A1

Co-PI; Project Leader
(Imaging CORE)

NIH, NINDS, Percent Effort: 12%

07/01/2013 06/30/2018

Imaging and Tissue Correlates to Optimize Management of Glioblastoma - Integrated imaging and tissue biomarkers in glioblastoma multiforme post therapy; The objective of this study is to determine whether the quantitative characteristics derived from metabolic neuroimaging parameters can be predictive of the biologic behavior of glioblastoma multiforme (GBM) post therapy. This is an important clinical question because although histologic grade at initial diagnosis is an important prognostic factor, there is tremendous heterogeneity in the histopathology of GBM that can be influenced by prior therapy. At re-operation post therapy, pathologic specimens often consist of both "tumor" and "necrosis" (treatment effect). There are currently no well-established biomarkers that are predictive of the behavior of disease post therapy or the subsequent clinical outcome. While standard MR imaging is used for clinical evaluation of GBM, it may both under- and over-estimate tumor burden post therapy. This is especially true following therapies such as radiosurgery, brachytherapy, and interstitially administered agents using convection enhanced delivery (CED) where treatment effects can result in enlarging enhancing masses. To date, biopsy or histologic confirmation of enhancing tissue remains the standard for assessing these masses; however, sampling error, inability to perform repeated samplings, as well as the limited ability of pathology to predicting the behavior of these masses, remain significant challenges.

2. 2P50CA097257-11A1

Co-Investigator

NIH, NCI, Percent Effort: 4%

07/01/2013 06/30/2018

SPORE: Brain Tumor SPORE Grant - Prognostic value of MRSI parameters for patients with gliomas; The goal of this study is to translate a new metabolic imaging modality into a tool for clinical management of patients with recurrent low-grade glioma. The objective of the study is to determine whether quantitative parameters derived from magnetic resonance spectroscopic imaging (MRSI) data are predictive of response to therapy for patients with low-grade glioma.

3. 1R01CA169316-01A1	Co-Investigator	Costello, Joseph (PI)
NIH, Percent Effort: 3%	07/01/2013	06/30/2018
Imaging Guided Genomics of Malignant Transformation		

4. 2R01CA127612-06	Co-Investigator	
NIH, Percent Effort: 2%	07/01/2013	06/30/2018
MR Metabolic Markers for Evaluation of Patients with Recurrent Glioma		

RESEARCH AWARDS - PAST

1. CC121010/NAGKC 12-01	(Co-Investigator)	
NIH, NINDS, Percent Effort: 12%	11/1/2012	10/31/2014
Multi-Mets Protocols 1 & 2 - North American Gamma Knife Consortium (PI: Barani, I); A randomized controlled study of neurocognitive outcomes in patients with five or more brain metastases treated with radiosurgery or whole-brain radiotherapy.		

2. SPORE	Co-Investigator	Berger, M (PI)
NIH, NCI, Percent Effort: 10%	05/01/2007	04/30/2012
Prognostic value of MRSI parameters for patients with gliomas		

3. PO1	Co-PI; Project Leader (Project 2)	Berger, M (PI)
NIH, NINDS, Percent Effort: 20%	07/01/2007	06/30/2012
Integrated imaging and tissue biomarkers in glioblastoma multiforme post therapy;		

4. RO1 CA127612-01A1	Co-Investigator	Nelson, S (PI)
NIH, NCI, Percent Effort:10%	12/1/2007	06/30/2012

Imaging biomarkers for improved management of patients with newly diagnosed GBM; The objective is to integrate metabolic and physiologic MR imaging data into the clinical management of patients with newly diagnosed GBM who are being treated with a combination of radiation, temozolamide and anti-angiogenic therapy

5.	Career Development Award NIH/NINDS K23 NS45013-02A1 Brain tumor imaging: Quantitative MRI and 1H MRS; Percent Effort:75%	Principal Investigator	08/01/2003	04/30/2008
6.	Career Development Award Brain Tumor SPORE NIH/NCI Validation of neuroimaging biomarkers of gliomas using molecular genetic analysis of image-guided tissue biopsy; Percent Effort: 5%	Principal Investigator	05/01/2005	04/30/2007
7.	Accelerate Brain Cancer Cure Private Foundation Grant Identification of prognostic surrogate markers in malignant gliomas by quantitative magnetic resonance imaging; Percent effort: 5%	Principal Investigator		
8.	Foundation Scholar GrantAward American Society of Neuroradiology Dynamic Contrast-enhanced T2*-weighted MRI and Histopathological Assessment of Experimental Gliomas; Percent Effort: 50%	Principle Investigator		
9.	Seed Grant Radiological Society of North America Dynamic, Contrast-Enhanced T2*-weighted MR Imaging of Intracranial Neoplasm: Differentiation between Radiation Necrosis and Recurrent Tumor Percent Effort: 30%			
10.	UOI CA81449	Co-Investigator		Prados (PI)

National Cancer Institute, NIH
Pediatric Brain Tumor Clinical Trial Consortium (PBTCTC);
Percent Effort: 2.5% (effort only)

PEER REVIEWED PUBLICATIONS

11. Wetzel SG, Johnson G, Tan AG, Cha S, Knopp EA, Lee VS, Thomasson D, Rofsky NM. Three-dimensional, T1-weighted gradient-echo imaging of the brain with a volumetric interpolated examination. *Amer J Neuroradiol* 2002;23:995-1002. PMID: 12202717
12. Yang S, Wetzel S, Law M, Zagzag D, Cha S. Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri. *AJNR Am J Neuroradiol.* 2002 Mar; 23(3):350-5. PMID: 11900998
13. Wetzel SG, Cha S?, Johnson G, Lee P, Law M, Kasow DL, Pierce SD, Xue X. Relative cerebral blood volume measurements in intracranial mass lesions: An interobserver and intraobserver reproducibility study. *Radiology* 2002;224:797-803.
14. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. *Radiology.* 2002 Mar; 222(3):715-21. PMID: 11867790
15. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: Dynamic contrast-enhanced susceptibility-weighted echo-planar Perfusion MR imaging. *Radiology* 2002;223:11-29. PMID: 11930044
16. Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. *Radiology.* 2002 Apr; 223(1):11-29. PMID: 11930044
17. Yang S, Wetzel S, Law M, Zagzag D, Cha S. Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri. *Amer J Neuroradiol* 2002;23:350-355.
18. Wetzel SG, Johnson G, Tan AG, Cha S, Knopp EA, Lee VS, Thomasson D, Rofsky NM. Three-dimensional, T1-weighted gradient-echo imaging of the brain with a volumetric interpolated examination. *AJNR Am J Neuroradiol.* 2002 Jun-Jul; 23(6):995-1002. PMID: 12063232
19. Saindane A, Cha S, Law M, Knopp EA, Zagzag D. Proton MR spectroscopy of tumefactive demyelinating lesions. *Amer J Neuroradiol* 2002;23:1378-1386. PMID: 12223381
20. Saindane AM, Cha S, Law M, Xue X, Knopp EA, Zagzag D. Proton MR spectroscopy of tumefactive demyelinating lesions. *AJNR Am J Neuroradiol.* 2002 Sep; 23(8):1378-86. PMID: 12223381
21. Wetzel SG, Cha S, Law M, Johnson G, Golfinos J, Lee P, Nelson PK. Preoperative evaluation of intracranial tumors with perfusion MR imaging and MR angiogram: A comparative study with digital subtraction angiography. *Amer J Neuroradiol* 2002;23:1767-1774.
22. Wetzel SG, Cha S, Johnson G, Lee P, Law M, Kasow DL, Pierce SD, Xue X. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. *Radiology.* 2002 Sep; 224(3):797-803. PMID: 12202717
23. Law M, Meltzer DE, Cha S. Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion. *Neuroradiology* 2002;44:986-989.
24. Wetzel SG, Cha S, Law M, Johnson G, Golfinos J, Lee P, Nelson PK. Preoperative assessment of intracranial tumors with perfusion MR and a volumetric interpolated examination: a comparative study with DSA. *AJNR Am J Neuroradiol.* 2002 Nov-Dec; 23(10):1767-74. PMID: 12427637

25. Law M, **Cha S**, Knopp E, Johnson G, Arnett J, Litt A. High-Grade Gliomas and Solitary Metastases: Differentiation by Using Perfusion and Proton Spectroscopic MR Imaging. *Radiology* 2002;222:715.
26. Law M, Yang S, Wang H, Babb J, Johnson G, **Cha S**, Knopp EA and Zagzag D. Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging. *Amer J Neuroradiol* 2003; 24:1989-1998
27. Wetzel SG, Law M, Lee VS, Cha S, Johnson G, Nelson K. Imaging of the intracranial venous system with a contrast-enhanced volumetric interpolated examination. *Eur Radiol*. 2003 May; 13(5):1010-8. PMID: 12695822
28. Wetzel SG, Law M, Lee VS, Cha S, Johnson G, Nelson PK. Imaging of the intracranial venous system with a contrast-enhanced volumetric interpolated examination. *European Radiology* 2003;13:1010-1018.
29. Kothary N, Law M, Cha S, Zagzag D. Conventional and perfusion MR imaging of parafalcine chondrosarcoma. *AJNR Am J Neuroradiol*. 2003 Feb; 24(2):245-8. PMID: 12591641
30. Lu S, Ahn D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of primary and metastatic brain tumors. *Amer J Neuroradiol* 2003;24:937-941.
31. Nelson SJ, Cha S. Imaging glioblastoma multiforme. *Cancer J*. 2003 Mar-Apr; 9(2):134-45. PMID: 12784879
32. Kothary N, Law M, Cha S, Zagzag D. Conventional and perfusion MR imaging of parafalcine chondrosarcoma. *Amer J Neuroradiol* 2003;24:245-248.
33. Baek WK, Kim D, Jung N, Yi YW, Kim JM, Cha SD, Bae I, Cho CH. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. *Am J Obstet Gynecol*. 2003 Mar; 188(3):634-9. PMID: 12634633
34. Nelson SJ, Cha S. Imaging glioblastoma multiforme. *Cancer J* 2003;9:134-145.
35. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. *Magn Reson Med*. 2003 May; 49(5):848-55. PMID: 12704767
36. Cha S, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH. Dynamic, Contrast- enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. *Magn Reson Med* 2003;49:848-855.
37. Lu S, Ahn D, Johnson G, Cha S. Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors. *AJNR Am J Neuroradiol*. 2003 May; 24(5):937-41. PMID: 12748097
38. Yang S, Law M, Zagzag D, Wu HH, Cha S, Golfinos JG, Knopp EA, Johnson G. Dynamic contrast enhanced perfusion MR imaging measurements of endothelial permeability: Differentiation between atypical and typical meningiomas. *Amer J of Neuroradiol* 2003;24:1554-1559.
39. Cha S. Perfusion MR imaging: basic principles and clinical applications. *Magn Reson Imaging Clin N Am*. 2003 Aug; 11(3):403-13. PMID: 14768726

40. Law M, Yang S, Wang H, Babb J, Johnson G, Cha S, Knopp EA, Zagzag D. Glioma grading: Sensitivity and predictive value of perfusion MRI and proton spectroscopic imaging compared with conventional MR imaging. *Amer J Neuroradiol* 2003;24:1989-1998.
41. Yang S, Law M, Zagzag D, Wu HH, Cha S, Golfinos JG, Knopp EA, Johnson G. Dynamic contrast-enhanced perfusion MR imaging measurements of endothelial permeability: differentiation between atypical and typical meningiomas. *AJNR Am J Neuroradiol*. 2003 Sep; 24(8):1554-9. PMID: 13679270
42. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. *AJNR Am J Neuroradiol*. 2003 Nov-Dec; 24(10):1989-98. PMID: 14625221
43. Cha S. Perfusion MR imaging of brain tumors. *Topics in MRI* 2004;15:279-289
44. Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. *Magn Reson Med*. 2004 May; 51(5):961-8. PMID: 15122678
45. Ware ML, Cha S, Gupta N, Perry VL. Radiation-induced atypical meningioma with rapid growth in a 13-year-old girl. Case report. *J Neurosurg Spine* 2004;100: 488-491.
46. Ware ML, Cha S, Gupta N, Perry VL. Radiation-induced atypical meningioma with rapid growth in a 13-year-old girl. Case report. *J Neurosurg*. 2004 May; 100(5 Suppl Pediatrics):488-91. PMID: 15287460
47. Johnson G, Wetzel SG, Cha S, Babb J, Tofts PS. Measuring blood volume and vascular transfer constant from dynamic, T2?-weighted contrast-enhanced MRI. *Magn Reson Med* 2004;51:961-968.
48. Cha S. Perfusion MR imaging of brain tumors. *Top Magn Reson Imaging*. 2004 Oct; 15(5):279-89. PMID: 15627003
49. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurement derived from dynamic susceptibility contrast enhanced MR imaging. *Amer J Neuroradiol* 2005;26:266-273.
50. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S, Croteau D, Puri RK, Chang SM. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. *J Neurosurg*. 2005 Feb; 102(2):267-75. PMID: 15739554
51. Li X, Vigneron DB, Cha S, Graves EE, Crawford F, Chang SM, Nelson SJ. Measurement of lactate and lipid in newly-diagnosed gliomas using 3D lactate-edited MRSI and ellipsoidal K-space sampling and their relationship with perfusion data. *Amer J Neuroradiol* 2005; 26: 760-769.
52. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. *AJNR Am J Neuroradiol*. 2005 Feb; 26(2):266-73. PMID: 15709123

53. Parney IF, Kunwar S, McDermott M, Berger MS, Prados M, Cha S, Croteau D, Chang SM. Neuroradiographic Changes Following Convection Enhanced Delivery (CED) of the Conjugated Toxin IL-13-PE38QQR For Recurrent Malignant Glioma. *J Neurosurg* 2005;102:267-275.
54. Li X, Vigneron DB, Cha S, Graves EE, Crawford F, Chang SM, Nelson SJ. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo. *AJNR Am J Neuroradiol*. 2005 Apr; 26(4):760-9. PMID: 15814918
55. Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le T, Lu Y, Nelson SJ, McKnight TR. Longitudinal Multivoxel MR Spectroscopy study of Pediatric Diffuse Brainstem Gliomas treated by Radiotherapy. *Int J Radiat Oncol Biol Phys* 2005;62:20-31.
56. Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. *Int J Radiat Oncol Biol Phys*. 2005 May 1; 62(1):20-31. PMID: 15850898
57. Oh J, Cha S, Aiken A, Han ET, Crane JC, Stainsby JA, Wright GA, Dillon WP, Nelson SJ. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. *J Magn Reson Imaging* 2005;21:701-708.
58. Cha S. Update on brain tumor imaging. *Curr Neurol Neurosci Rep*. 2005 May; 5(3):169-77. PMID: 15865882
59. Lupo J, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. *Amer J of Neuroradiol* 2005;26:1446-1454.
60. Lee MC, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases. *J Magn Reson Imaging*. 2005 Jun; 21(6):683-93. PMID: 15906330
61. Lee MC, Chang SM, Cha S, Nelson SJ. Dynamic susceptibility contrast perfusion imaging radiation effects in normal appearing brain tissue: changes in the first-pass and recirculation phases. *J Magn Reson Imaging* 2005;21:683-693.
62. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. *AJNR Am J Neuroradiol*. 2005 Jun-Jul; 26(6):1446-54. PMID: 15956514
63. Smith J, Cha S, Mayo MC, McDermott MW, Parsa AT, Dillon WP, Berger MS. Serial diffusion-weighted MR imaging of gliomas: Distinguishing tumor recurrence from post-resection injury. *J Neurosurg* 2005;103:428-438.
64. Oh J, Cha S, Aiken AH, Han ET, Crane JC, Stainsby JA, Wright GA, Dillon WP, Nelson SJ. Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. *J Magn Reson Imaging*. 2005 Jun; 21(6):701-8. PMID: 15906339
65. Smith JS, Cha S, Mayo MC, McDermott MW, Parsa AT, Chang SM, Dillon WP, Berger MS. Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. *J Neurosurg*. 2005 Sep; 103(3):428-38. PMID: 16235673

66. *Jun P, Garcia J, Tihan T, McDermott M, Cha S. Perfusion MR Imaging of an intracranial collision tumor confirmed by image-guided Biopsy: Case report. *Amer J Neuroradiol* 2006;27:94-97.
67. Sanchez-Mejia RO, Pham DN, Prados M, Tihan T, Cha S, El-Sayed I, McDermott MW. Management of a sporadic malignant subfrontal peripheral nerve sheath tumor. *J Neurooncol*. 2006 Jan; 76(2):165-9. PMID: 16132491
68. *Cha S, Yang L, Johnson G, Lai A, Chen M, Tihan T, Wendland M, Dillon WP. Comparison of microvascular permeability measurements, Ktrans, determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. *Amer J Neuroradiol* 2006;27:409-417.
69. Waldron JS, Cha S. Radiographic features of intramedullary spinal cord tumors. *Neurosurg Clin N Am*. 2006 Jan; 17(1):13-9. PMID: 16448903
70. Lee MC, Cha S, Chang S, Nelson SJ. Partial-volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas. *J Magn Reson Imaging* 2006;23:257-266
71. Cha S. Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in pediatric patients. *Neuroimaging Clin N Am*. 2006 Feb; 16(1):137-47, ix. PMID: 16543089
72. Sanchez-Mejia RO, Pham DN, Prados M, Tihan T, Cha S, El-Sayed I, McDermott MW. Management of a sporadic malignant subfrontal peripheral nerve sheath tumor. *J Neurooncol* 2006;76:165-169.
73. Lee MC, Cha S, Chang SM, Nelson SJ. Partial-volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas. *J Magn Reson Imaging*. 2006 Mar; 23(3):257-66. PMID: 16456821
74. Ozturk-Isik E, Cha S, Chang SM, Berger MS, Nelson SJ. Lipid Unaliasing for MR Spectroscopic Imaging of Gliomas at 3T Utilizing Sensitivity Encoding (SENSE). *Magn Reson Med* 2006;55:1164-1169.
75. Cha S. CNS tumors: monitoring therapeutic response and outcome prediction. *Top Magn Reson Imaging*. 2006 Apr; 17(2):63-8. PMID: 17198223
76. Cianfoni A, Cha S, Bradley WG, Dillon WP, Wintermark M. Quantitative measurement of blood-brain barrier permeability using perfusion-CT in extra-axial brain tumors. *J Neuroradiol* 2006;33:164-168
77. Smith JS, Lin H, Mayo MC, Bannerjee A, Gupta N, Perry V, Cha S. Diffusion-weighted MR imaging abnormalities in pediatric patients with surgically-treated intracranial mass lesions. *J Neurooncol*. 2006 Sep; 79(2):203-9. PMID: 16598419
78. Waldron JS, Cha S. Radiographic features of intramedullary spinal cord tumors. *Neurosurg Clin N Am* 2006;17:13-19
79. Ozturk-Isik E, Crane JC, Cha S, Chang SM, Berger MS, Nelson SJ. Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE). *Magn Reson Med*. 2006 May; 55(5):1164-9. PMID: 16596629
80. Smith JS, Lin H, Mayo MC, Bannerjee A, Gupta N, Perry V, Cha S?. Diffusion-weighted MR imaging abnormalities in pediatric patients with surgically-treated intracranial mass lesions. *J Neurooncol* 2006;79: 203-209.

81. Smith JS, Quiñones-Hinojosa A, Phillips JJ, Bollen AW, McDermott MW, Cha S. Limitations of diffusion-weighted imaging in distinguishing between a brain tumor and a central nervous system histoplasma. *J Neurooncol*. 2006 Sep; 79(2):217-8. PMID: 16850113
82. Lupo JM, Lee MC, Han ET, Cha S, Chang S, Berger MS, Nelson SJ. Feasibility of dynamic susceptibility-contrast perfusion MR imaging at 3T using a standard quadrature head coil and 8-channel phased-array coil with and without SENSE reconstruction. *J of Magn Reson Imaging* 2006;24:520-9.
83. Lupo JM, Lee MC, Han ET, Cha S, Chang SM, Berger MS, Nelson SJ. Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction. *J Magn Reson Imaging*. 2006 Sep; 24(3):520-9. PMID: 16888776
84. Li Y, Osorio JA, Ozturk E, Chen A, Xu D, Crane JC, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ. Considerations in applying 3-D PRESS H-1 MRSI for studies of patients with brain tumors at 3T relative to 1.5T. *Magn Reson Imaging* 2006; 24:1295-1302.
85. Li Y, Osorio JA, Ozturk-Isik E, Chen AP, Xu D, Crane JC, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ. Considerations in applying 3D PRESS H-1 brain MRSI with an eight-channel phased-array coil at 3 T. *Magn Reson Imaging*. 2006 Dec; 24(10):1295-302. PMID: 17145400
86. Smith JS, Quinones-Hinojosa A, Phillips JJ, Bollen AW, McDermott MW, Cha S. Limitations of diffusion-weighted imaging in distinguishing between a brain tumor and a central nervous system histoplasma. *J Neurooncol* 2006;79:217-218
87. Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim NH, Cha SY, Ryu JK, Choi YJ, Kim J, Fearon ER, Weiss SJ. A Wnt-Axin2-GSK3beta cascade regulates Snail1 activity in breast cancer cells. *Nat Cell Biol*. 2006 Dec; 8(12):1398-406. PMID: 17072303
88. Martin AJ, Cha S, Higashida RT, Cullen SP, Halbach V, Dowd CF, McDermott MW, Saloner DA. Assessment of vasculature of meningiomas and the effects of embolization with intra-arterial MR perfusion imaging: a feasibility study. *Amer J Neuroradiol* 2007;28:1771-1777
89. Ware ML, Hirose Y, Scheithauer BW, Yeh RF, Mayo MC, Smith JS, Chang S, Cha S, Tihan T, Feuerstein BG. Genetic aberrations in gliomatosis cerebri. *Neurosurgery*. 2007 Jan; 60(1):150-8; discussion 158. PMID: 17228264
90. Cha S, Lupo JM, Chen M, Lamborn KR, McDermott MW, Berger MS, Nelson SJ, Dillon WP. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percent signal recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. *Amer J Neuroradiol*. 2007;28:1078-1084
91. Osorio JA, Ozturk-Isik E, Xu D, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ. 3D 1H MRSI of brain tumors at 3.0 Tesla using an eight-channel phased-array head coil. *J Magn Reson Imaging*. 2007 Jul; 26(1):23-30. PMID: 17659562
92. Lupo JM, Cha S, Chang SM, Nelson SJ. Analysis of metabolic indices in regions of abnormal perfusion in high-grade glioma patients. *J Magn Reson Imaging* 2007;28:1455-61.

93. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, VandenBerg S, Berger MS. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. *Neuro Oncol.* 2007 Oct; 9(4):424-9. PMID: 17622647. PMCID: PMC1994099
94. Lim DA, Cha S, Mayo MC, Chen MH, Keles E, Vandenberg S, Berger MS. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. *Neuro Oncol* 2007;9:424-429.
95. Osorio JA, Ozturk-Isik E, Xu D, Cha S, Chang S, Berger MS, Vigneron DB, Nelson SJ. 3D (1)H MRSI of brain tumors at 3.0 tesla using an eight-channel phased-array head coil. *J Magn Reson Imaging* 2007;26:23-30.
96. Ware ML, Hirose Y, Scheithauer BW, Yeh RF, Mayo MC, Smith JS, Chang S, Cha S, Tihan T, Feuerstein BG. Genetic aberrations in gliomatosis cerebri. *Neurosurgery* 2007;60:150-158.
97. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, and Kuo MD. Identification of non-invasive imaging surrogates for brain tumor gene expression modules. *Proceedings of the National Academy of Sciences* 2008;105:5213-8
98. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. *J Clin Oncol.* 2008 Mar 10; 26(8):1338-45. PMID: 18323558
99. Aiken AH, Chang SM, Larson D, Butowski N, Cha S. Longitudinal MRI features of glioblastoma multiforme treated with radiation therapy with or without brachytherapy. *Int J Radiat Oncol Biol Phys* 2008;72:1340-46.
100. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, Aldape K, Cha S, Kuo MD. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proc Natl Acad Sci U S A.* 2008 Apr 1; 105(13):5213-8. PMID: 18362333. PMCID: PMC2278224
101. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. *J Clin Oncol* 2008; 26:1338-45.
102. Khayal IS, Crawford FW, Saraswathy S, Lamborn KR, Chang SM, Cha S, McKnight TR, Nelson SJ. Relationship between choline and apparent diffusion coefficient in patients with gliomas. *J Magn Reson Imaging.* 2008 Apr; 27(4):718-25. PMID: 18383265. PMCID: PMC3030277
103. *Khayal IS, Crawford FW, Saraswathy S, Lamborn KR, Chang SM, **Cha S**, McKnight TR, Nelson SJ. Relationship between choline and apparent diffusion coefficient in patients with gliomas. *J Magn Reson Imaging.* 2008 Apr;27(4):718-25. doi: 10.1002/jmri.21288.
104. Aiken AH, Chang SM, Larson D, Butowski N, Cha S. Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. *Int J Radiat Oncol Biol Phys.* 2008 Dec 1; 72(5):1340-6. PMID: 18538496
105. *Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S. Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging. 2009; 30:367-372.

106. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. *J Neurooncol*. 2009 Jan; 91(1):69-81. PMID: 18810326. PMCID: PMC3022437
107. *Barajas RF, Chang JS, Segal MR, Parsa A, McDermott MW, Berger M, Cha S. Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis Following External Beam Radiation Therapy Using Dynamic Susceptibility Weighted Contrast-Enhanced Perfusion MR Imaging. *Radiology* 2009; 253: 489-496.
108. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. *J Neurooncol*. 2009 Feb; 91(3):337-51. PMID: 19009235. PMCID: PMC3022444
109. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. *J Neurooncol* 2009;91:69-81.
110. Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghi M, Clarke J, Berger M. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. *J Neurooncol*. 2009 May; 92(3):401-15. PMID: 19357966. PMCID: PMC2834319
111. *Barajas RF, Collins E, Cha S, Gerschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. *Epilepsia* 2009;51:473-477
112. Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ. Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas. *NMR Biomed*. 2009 May; 22(4):449-55. PMID: 19125391. PMCID: PMC3772178
113. Chang SM, Nelson S, Vandenberg S, Cha S, Prados M, Butowski N, McDermott M, Parsa AT, Aghil M, Clarke J, Berger M. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. *J Neurooncol* 2009;92:401-15.
114. Cha S. Neuroimaging in neuro-oncology. *Neurotherapeutics*. 2009 Jul; 6(3):465-77. PMID: 19560737
115. *Bian W, Khayal IS, Lupo J, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ. Multiparametric Characterization of Grade 2 Glioma Subtypes Using Magnetic Resonance Spectroscopic, Perfusion, and Diffusion Imaging. *Transl Oncol* 2009; 2:271-280.
116. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. *Neuro Oncol* 2009;11:842-52.
117. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ. Relationship of [re-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. *J Neurooncol* 2009;91:337-351.
118. Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn KR, Chang SM, **Cha S**, Nelson SJ. Apparent diffusion coefficient and fractional anisotropy of newly diagnosed

- grade II gliomas. *NMR Biomed.* 2009 May;22(4):449-55. PMID: 19125391 [PubMed - indexed for MEDLINE]
119. Khayal IS, McKnight TR, McGue C, Vandenberg S, Lamborn KR, Chang S, Cha S, Nelson SJ. Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas. *NMR Biomed* 2009;22:449-455.
 120. *Barajas RF, Rubenstein J, Chang JS, Whang J, Cha S. Diffusion weighted MR imaging derived minimum apparent diffusion coefficient within contrast enhancing region is predictive of clinical outcome in primary central nervous system lymphoma. *Amer J Neuroradiol* 2010; 31:60-66.
 121. Barajas RF, Chang JS, Segal MR, Parsa AT, McDermott MW, Berger MS, Cha S. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. *Radiology.* 2009 Nov; 253(2):486-96. PMID: 19789240. PMCID: PMC2770116
 122. Bian W, Khayal IS, Lupo JM, McGue C, Vandenberg S, Lamborn KR, Chang SM, Cha S, Nelson SJ. Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging. *Transl Oncol.* 2009 Dec; 2(4):271-80. PMID: 19956389. PMCID: PMC2781083
 123. Pirzkall A, McGue C, Saraswathy S, Cha S, Liu R, Vandenberg S, Lamborn KR, Berger MS, Chang SM, Nelson SJ. Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. *Neuro Oncol.* 2009 Dec; 11(6):842-52. PMID: 19229057. PMCID: PMC2802404
 124. Barajas RF, Collins DE, Cha S, Geschwind MD. Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. *Epilepsia.* 2010 Mar; 51(3):473-7. PMID: 19780798. PMCID: PMC2907153
 125. *Barajas RF, Hodgson G, Chang JS, Vandenberg S, Yeh RF, Parsa A, McDermott M, Berger M, Dillon W, Cha S. Anatomic and physiologic MR imaging is influenced by glioblastoma multiforme regional genetic and cellular expression patterns. *Radiology* 2010;254:564-576.
 126. Barajas RF, Hodgson JG, Chang JS, Vandenberg SR, Yeh RF, Parsa AT, McDermott MW, Berger MS, Dillon WP, Cha S. Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. *Radiology.* 2010 Feb; 254(2):564-76. PMID: 20093527. PMCID: PMC2809924
 127. *Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski BA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. *Neuro Oncol* 2010; [Epub ahead of print]
 128. Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. *Neuro Oncol.* 2010 Sep; 12(9):908-16. PMID: 20501631. PMCID: PMC2940691
 129. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. *Neuro Oncol* 2010; [Epub ahead of print]

130. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. *Neuro Oncol.* 2010 Nov; 12(11):1152-61. PMID: 20647244. PMCID: PMC3098023
131. Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, **Cha S**, Chang SM, Nelson SJ. Ex Vivo MR Spectroscopic Measure Differentiates Tumor from Treatment Effects in GBM. *Neuro Oncology.* 2010 Nov;12(11):1152-61. Epub 2010 Jul 20.
132. *Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, **Cha S**, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. *Neuro Oncol.* 2010 Sep;12(9):908-16. doi: 10.1093/neuonc/noq049. Epub 2010 May 25.
133. *Bian W., **Cha S.**, Chang S., Crane JC, Li Y., Lupo JM, Polley MY, Nelson SJ. Serial Analysis of Imaging Parameters in Patients with Newly Diagnosed Glioblastoma Multiforme. *Neuro Oncology.* 2011 Feb 4. [Epub ahead of print]
134. Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. *Neuro Oncol.* 2011 Jan; 13(1):119-31. PMID: 21036812. PMCID: PMC3018901
135. Poussaint TY., Kocak M., Vajapeyam S., Packer RI., Robertson RL., Geyer R., Haas-Kogan D., Pollack IF., Vezina G., Zimmerman R., **Cha S.**, Patay Z., Boyett JM., Kun LE., MRI as a Central Component of Clinical Trials Analysis in Brainstem Glioma: a Report From the Pediatric Brain Tumor Consortium (PBTC). *Neuro Oncology.* 2011 Feb 4. [Epub ahead of print]
136. Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson RL, Geyer R, Haas-Kogan D, Pollack IF, Vezina G, Zimmerman R, Cha S, Patay Z, Boyett JM, Kun LE. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). *Neuro Oncol.* 2011 Apr; 13(4):417-27. PMID: 21297126. PMCID: PMC3064695
137. *Essock-Burns E., Lupo JM., **Cha S.**, Polley MY., Butowski NA., Chang SM., Nelson SJ., Assessment of Perfusion MRI-Derived Parameters in Evaluating and Predicting Response to Antiangiogenic Therapy in Patients with Newly Diagnosed Glioblastoma. *Neuro Oncology.* 2011 Jan; 13(1):119-31. Epub 2010 Oct. 29
138. Li Y, Lupo JM, Polley MY, Crane JC, Bian W, Cha S, Chang S, Nelson SJ. Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. *Neuro Oncol.* 2011 May; 13(5):546-57. PMID: 21297128. PMCID: PMC3093330
139. *Khayal IS; Vandenberg S; Smith K; Cloyd C; Chang S; **Cha S**; Nelson SJ; McKnight TR, MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. *Neuro-Oncology* 2011; doi: 10.1093/neuonc/nor122
140. Khayal IS, Vandenberg SR, Smith KJ, Cloyd CP, Chang SM, Cha S, Nelson SJ, McKnight TR. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. *Neuro Oncol.* 2011 Nov; 13(11):1192-201. PMID: 21865401. PMCID: PMC3199150

141. *Barajas RF, **Cha S**. Imaging diagnosis of brain metastasis. *Prog Neurol Surg*. 2012; 25:55-73.
142. Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, Cha S, Chang SM, Nelson SJ. Regional variation in histopathologic features of tumor specimens from treatment-naïve glioblastoma correlates with anatomic and physiologic MR Imaging. *Neuro Oncol*. 2012 Jul; 14(7):942-54. PMID: 22711606. PMCID: PMC3379808
143. *Barajas RF, Cha S. Imaging diagnosis of brain metastasis. *Prog Neurol Surg*. 2012; 25:55-73. PMID: 22236668
144. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, **Cha S**, Nelson SJ. Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas. *Sci Transl Med*. 2012 Jan 11; 4(116):116ra5.
145. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. *Sci Transl Med*. 2012 Jan 11; 4(116):116ra5. PMID: 22238333. PMCID: PMC3772177
146. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, **Cha S**, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. *Clin Cancer Res*. 2012 Feb 15; 18(4):1146-55.
147. Ozturk-Isik E, Pirzkall A, Lamborn KR, Cha S, Chang SM, Nelson SJ. Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. *Transl Oncol*. 2012 Feb; 5(1):10-8. PMID: 22348171. PMCID: PMC3281410
148. Ozturk-Isik E, Pirzkall A, Lamborn KR, **Cha S**, Chang SM, Nelson SJ. Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging. *Transl Oncol*. 2012 Feb; 5(1):10-8.
149. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, Cha S, Chang SM, Bajcsy R, Nelson SJ. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. *Artif Intell Med*. 2012 May; 55(1):61-70. PMID: 22387185. PMCID: PMC3314104
150. Constantin A, Elkhaled A, Jalbert L, Srinivasan R, **Cha S**, Chang SM, Bajcsy R, Nelson SJ. Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy. *Artif Intell Med*. 2012 May; 55(1):61-70.
151. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburg J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. *J Neurooncol*. 2012 Jul; 108(3):491-8. PMID: 22426926. PMCID: PMC3997502
152. Hasan DM, Amans M, Tihan T, Hess C, Guo Y, **Cha S**, Su H, Martin AJ, Lawton MT, Neuwelt EA, Saloner DA, Young WL. Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation. *Transl Stroke Res*. 2012 Jul; 3 (Supplement 1): 166-173. PMID: 23002401[PubMed]

153. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, **Cha S**, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Rn PL, Prados M, Goldin J, Wen PY, Cloughesy T. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. *J Neurooncol*. 2012 Jul; 108(3):491-8.
154. Hasan DM, Amans M, Tihan T, Hess C, Guo Y, Cha S, Su H, Martin AJ, Lawton MT, Neuwelt EA, Saloner DA, Young WL. Ferumoxytol-enhanced MRI to Image Inflammation within Human Brain Arteriovenous Malformations: A Pilot Investigation. *Transl Stroke Res*. 2012 Jul; 3(Suppl 1):166-73. PMID: 23002401. PMCID: PMC3445332
155. *Barajas RF, Phillips JJ, Parvataneni R, Molinaro A, Essock-Burns E, Bourne G, Parsa AT, Aghi MK, McDermott MW, Berger MS, **Cha S**, Chang SM, Nelson SJ. Regional variation in histopathologic features of tumor specimens from treatment-naïve glioblastoma correlates with anatomic and physiologic MR Imaging. *Neuro Oncol*. 2012 Jul; 14(7):942-54. PMID: 22711606
156. Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. *J Neurosurg*. 2012 Dec; 117(6):1032-8. PMID: 23039151
157. *Barajas RF, Perry A, Sughrue M, Aghi M, **Cha S**. Intracranial subdural osteoma: A rare benign tumor that can be differentiated from other calcified intracranial lesions utilizing MR imaging. *J Neuroradiol*. 2012 Oct; 39(4):263-6.
158. Bloch O, Han SJ, **Cha S**, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT. Impact of extent of resection for recurrent glioblastoma on overall survival. *J Neurosurg*. 2012 Dec; 117(6):1032-8. PMID: 23039151
159. *Jafri NF, Clarke JL, Weinberg V, Barani IJ, **Cha S**. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. *Neuro Oncol*. 2013 Jan; 15(1):91-6. PMID: 23095230
160. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. *Neuro Oncol*. 2013 Jan; 15(1):91-6. PMID: 23095230. PMCID: PMC3534420
161. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, **Cha S**, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. *Blood*. 2013 Jan 31; 121(5):745-51. PMID: 23197589
162. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. *Blood*. 2013 Jan 31; 121(5):745-51. PMID: 23197589. PMCID: PMC3563362
163. Lupo JM, Essock-Burns E, Molinaro AM, **Cha S**, Chang SM, Butowski N, Nelson SJ. Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. *Neuro Oncol*. 2013 Apr; 15(4):480-9. PMID: 23393208
164. Essock-Burns E, Phillips JJ, Molinaro AM, Lupo JM, Cha S, Chang SM, Nelson SJ. Comparison of DSC-MRI post-processing techniques in predicting microvascular

- histopathology in patients newly diagnosed with GBM. *J Magn Reson Imaging*. 2013 Aug; 38(2):388-400. PMID: 23281184. PMCID: PMC3711964
165. Li Y, Lupo JM, Parvataneni R, Lamborn KR, **Cha S**, Chang SM, Nelson SJ. Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging. *Neuro Oncol*. 2013 May; 15(5):607-17. PMID: 23393206
 166. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, **Cha S**, Hwang JH, Cinque P, Cyster JG, Lowell C. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. *Blood*. 2013 Jun 6; 121(23):4740-8. PMID: 23570798.
 167. *Essock-Burns E, Phillips JJ, Molinaro AM, Lupo JM, **Cha S**, Chang SM, Nelson SJ. Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM. *J Magn Reson Imaging*. 2013 Aug; 38(2):388-400. PMID: 23281184
 168. *Ali S, Joseph NM, Perry A, Barajas RF Jr., **Cha S**. Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. *J Neurooncol* 2014;119:353-360 PMID: 24893732
 169. Johnson BE, Mazar T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, Asthana S, Jalbert LE, Nelson SJ, Bollen AW, Gustafson WC, Charron E, Weiss WA, Smirnov IV, Song JS, Olshen AB, **Cha S**, Zhao Y, Moore RA, Mungall AJ, Jones SJ, Hirst M, Marra MA, Saito N, Aburatani H, Mukasa A, Berger MS, Chang SM, Taylor BS, Costello JF. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science*. 2014 Jan 10; 343(6167):189-93. PMID: 24336570
 170. *Ali S, Joseph NM, Perry A, Barajas RF, Cha S. Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. *J Neurooncol*. 2014 Sep; 119(2):353-60. PMID: 24893732
 171. Sayegh ET, Henderson GA, Burch EA, Reis GF, **Cha S**, Oh T, Bloch O, Parsa AT. Intrameningioma metastasis of breast carcinoma. *Rare Tumors*. 2014 May 13; 6(2):5313. PMID: 25002947.
 172. *Barajas RF, Cha S. Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy. *CNS Oncol*. 2014 Nov; 3(6):407-19. PMID: 25438812. PMCID: PMC4277861
 173. Kadoch C, Li J, Wong VS, Chen L, **Cha S**, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. *Clin Cancer Res*. 2014 Feb 15; 20(4):1029-41. PMID: 24190981.
 174. Rolston JD, Englot DJ, Benet A, Li J, Cha S, Berger MS. Frontal operculum gliomas: language outcome following resection. *J Neurosurg*. 2015 Apr; 122(4):725-34. PMID: 25635477
 175. *Barajas RF Jr, Phillips JJ, Vandenberg SR, McDermott MW, Berger MS, Dillon WP, **Cha S**. Pro-angiogenic cellular and genomic expression patterns within glioblastoma influences dynamic susceptibility weighted perfusion MRI. *Clin Radiol*. 2015 Jul 28. PubMed PMID: 26231469.
 176. *Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. Assessing Biological Response to Bevacizumab Using

- 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. *Case Rep Radiol.* 2015; 2015:731361. PMID: 25793136. PMCID: PMC4352456
177. Horton JC, Douglas VC, Cha S. Reduced apparent diffusion coefficient in neuromyelitis optica-associated optic neuropathy. *J Neuroophthalmol.* 2015 Mar; 35(1):101-2. PMID: 25574902. PMCID: PMC4654107
 178. *Mabray MC, Barajas RF, Cha S. Modern brain tumor imaging. *Brain Tumor Res Treat.* 2015 Apr; 3(1):8-23. PMID: 25977902. PMCID: PMC4426283
 179. Breshears JD, Rutkowski MJ, McDermott MW, Cha S, Tihan T, Theodosopoulos PV. Surgical Management of Intracranial Neuroenteric Cysts: The UCSF Experience. *J Neurol Surg B Skull Base.* 2015 Dec; 76(6):475-9. PMID: 26682127. PMCID: PMC4671887
 180. *Villanueva-Meyer JE, Cha S. From Shades of Gray to Microbiologic Imaging: A Historical Review of Brain Abscess Imaging: RSNA Centennial Article. *Radiographics.* 2015 Sep-Oct; 35(5):1555-62. PMID: 26207582
 181. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro Oncol.* 2015 Sep; 17(9):1188-98. PMID: 26250565. PMCID: PMC4588759
 182. Pastula DM, Burish M, Reis GF, Bollen A, Cha S, Ralph J, Douglas VC. Adult-onset central nervous system hemophagocytic lymphohistiocytosis: a case report. *BMC Neurol.* 2015; 15:203. PMID: 26467435. PMCID: PMC4606887
 183. *Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. *AJR Am J Roentgenol.* 2015 Nov; 205(5):1075-85. PMID: 26496556. PMCID: PMC4679155
 184. *Mabray MC, Cha S. CNS angiitis as a brain tumor mimic with a branching vascular abnormality on T2* MRI. *Neurology.* 2015 Nov 17; 85(20):1819-20. PMID: 26574536. PMCID: PMC4653101
 185. Lupo JM, Molinaro AM, Essock-Burns E, Butowski N, Chang SM, Cha S, Nelson SJ. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma†. *Neuro Oncol.* 2016 Jan; 18(1):87-95. PMID: 26206774. PMCID: PMC4677411
 186. * First author was a trainee mentored and supervised by me and I was the corresponding author.

NON-PEER REVIEWED PUBLICATIONS

1. **Cha S.** Perfusion MR imaging: basic principles and clinical applications. *Magn Reson Imaging Clin N Am* 2003;11:403-413.
2. **Cha S.** Update on brain tumor imaging. *Curr Neurol Neurosci Rep* 2005;5:169-177
3. **Cha S.** Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in pediatric patients. *Neuroimaging Clin N Am* 2006;16:137-147

4. **Cha S.** Update on brain tumor imaging: from anatomy to physiology. *AJNR Amer J Neuroradiol* 2006;27:475-487
5. **Cha S.** CNS tumors: Monitoring therapeutic response and outcome prediction. *Topics in Magnetic Resonance Imaging* 2006;17:63-68
6. **Cha S.** Neuroimaging in Neuro-Oncology. *Neurotherapeutics* 2009; 6:465-477.
7. **Cha S.** Special Collections: Brain Tumor Imaging: Pre-therapy. *Amer J Neuroradiol* April 2010
8. **Cha S.** Special Collections: Brain Tumor Imaging: Post-therapy. *Amer J Neuroradiol* November 2010

REVIEW ARTICLES

1. George AE, **Cha S.** Applying functional MR to brain - Behavior research. Can we do better than simple clinical measures. Editorial for Capizzano et al Subcortical ischemic vascular dementia: Assessment with quantitative MRI and 1HMRSI. *Amer J of Neuroradiol* 2000;21;619-620
2. George AE, **Cha S.** What role does functional MR imaging play in the diagnosis or prediction of future-onset Alzheimer's disease? *Amer J of Neuroradiol* 2001;22:1017-1018.
3. **Cha S.** Relative recirculation: What does it mean? *Amer J of Neuroradiol* 2002;23:1-2
4. **Cha S.** T2*-weighted Cerebral Perfusion Maps of Gliomas. American Society of Neuroradiology (ASNR) Education and Research Symposium 2001. Syllabus pp.21-26
5. **Cha S.** Anatomic and Functional Imaging in the Planning of Conformal Radiation Therapy. ASNR Education and Research Symposium 2004. Syllabus pp.34-38
6. **Cha S.** Perfusion MR Imaging of Brain Tumors: Theory and Practical Applications. Oncologic Imaging. American Roentgen Ray Society 103rd Annual Meeting 2003. Categorical Course Syllabus pp.25-33

BOOKS AND CHAPTERS

1. **Cha S.** Diagnostic Imaging. In: Berger MS, Prados M, eds. *Textbook of Neuro-Oncology, Part 1: Basic Principle*, Elsevier 2004
2. Bryant SO, **Cha S**, Barkovich AJ. Modern Neuroimaging of Pediatric CNS Tumors. In: Gupta N, Banerjee A, Haas-Kogan D, eds. *Pediatric CNS Tumors*. Springer-Verlag 2004
3. **Cha S.** Brain Tumor Imaging. In: Medina S, Blackmore C, eds. *Evidence-based Imaging*. Springer-Verlag 2006
4. **Cha S.** Brain Tumor Imaging. In: Medina S, Applegate K, Blackmore C, eds. *Evidence-based Imaging in Pediatrics*. Springer-Verlag 2009
5. Editors: Naidich T, Castillo M, **Cha S.** *Imaging of the Brain*. Elsevier Health Sciences (Publication date: April 2010)
6. Editors: Kollias S, Castillo M, Raybaud C, Smirniotopoulos J, **Cha S.** Saunders. *Imaging of the Spine*. (publication date: October 2010)

SIGNIFICANT PUBLICATIONS

1. **Cha S**, Johnson G, Wadghiri YZ, Jin O, Babb J, Zagzag D, Turnbull DH. Dynamic, Contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. *Magn Reson Med* 2003;49:848-855.

First author and contributed to the design of the study, literature search, data acquisition and analysis, and manuscript preparation and editing.

2. ***Cha S**, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurement derived from dynamic susceptibility contrast enhanced MR imaging. *Amer J Neuroradiol* 2005;26:266-273.

First author and contributed to the design of the study, literature search, data acquisition and analysis, and manuscript preparation and editing.

3. ***Cha S**, Yang L, Johnson G, Lai A, Chen M, Tihan T, Wendland M, Dillon WP. Comparison of microvascular permeability measurements, K^{trans} , determined with conventional steady-state T1-weighted and first-pass T2*-weighted MR imaging methods in gliomas and meningiomas. *Amer J Neuroradiol* 2006;27:409-417.

First author and contributed to the design of the study, literature search, data acquisition and analysis, and manuscript preparation and editing.

4. *Barajas RF, Rubenstein J, Chang JS, Whang J, **Cha S**. Diffusion weighted MR imaging derived minimum apparent diffusion coefficient within contrast enhancing region is predictive of clinical outcome in primary central nervous system lymphoma. *Amer J Neuroradiol* 2010; 31:60-66.

Supervising senior author with resident and corresponding author. Contributed to the design of the study, literature search, data acquisition and analysis, and manuscript preparation and editing.

5. *Barajas RF, Hodgson G, Chang JS, Vandenberg S, Yeh RF, Parsa A, McDermott M, Berger M, Dillon W, **Cha S**. Anatomic and physiologic MR imaging is influenced by glioblastoma multiforme regional genetic and cellular expression patterns. *Radiology* 2010;254:564-576.

Supervising senior author with resident and corresponding author. Contributed to the design of the study, literature search, data acquisition and analysis, and manuscript preparation and editing.

CONFERENCE ABSTRACTS

1. **Cha S**, Kalina P, Black K, Woldenberg R. Spontaneous juxtaseellar carotid dural fistula following resection of a meningioma. Exerpta Extraordinaire presented at the American Society of Head and Neck Society, Los Angeles, CA, April, 1996.
2. **Cha S**, Johnson G, Yuz M, et al. The role of contrast-enhanced perfusion MR imaging in differentiating between recurrent brain tumor and radiation necrosis. Scientific paper to be presented at the 85th Scientific Assembly and Annual Meeting of the Radiological Society of North America, November 1999.
3. Frazzini VI, **Cha S**, Lu S, et al. Dynamic contrast-enhanced T2*-weighted echo-planar perfusion MR imaging of primary CNS lymphoma and glioblastoma multiforme. Scientific paper presented at the 37th annual meeting of the American Society of Neuroradiology, San Diego, CA, 1999.

4. **Cha S**, Knopp EA, Litt AW, Johnson G, Ton A, Yang C, Zagzag D. Dynamic contrast-enhanced T2*-weighted echo-planar perfusion MR imaging of extraaxial neoplasms. Scientific paper presented at the 38th annual meeting of the American Society of Neuroradiology, Atlanta, GA, April 2000.
5. Tofts PS, **Cha S**, Johnson G. A simple model to characterize blood-brain barrier leakage from T2*-weighted bolus tracking MRI. Scientific paper at the Workshop on MR in experimental and clinical cancer research in the new millennium, Syllabus, p58. International Society for Magnetic Resonance in Medicine, Geiranger, Norway, August 2000
6. Jun P, **Cha S**, Tihan T, Chang J, Chang S, Prados MD, Dillon WP, and Berger MS. Recurrent high-grade glioma and therapy-related necrosis: Differentiation based on quantitative perfusion MR imaging. Society of Neurooncology 2004
7. Chang J, **Cha S**, Li X, Sadarangani P, Chang S, Nelson S. Separate Quantification of Lactate and Lipid in Treatment-Naive High-Grade Gliomas Using 3D MRSI. The Society of Neurooncology 2004
8. Hoxworth JM, **Cha S**, Butowski N, Chang S, Chang J, Vigneron DB, Li X, Berger MS, Nelson SJ. Lactate-edited MRSI: Increased lactate in high grade gliomas prior to radiotherapy predicts early treatment failure. The Society of Neurooncology 2004, Toronto, Canada
9. Mayo K, Lupo J, Butowski N, Chang S, Prados M, Larson D, Nelson S, Berger MS, **Cha S**. Longitudinal quantitation of tumor hemodynamics using bolus tracking perfusion MR imaging in patients with newly diagnosed glioblastoma multiforme undergoing radiation therapy. The Society of Neurooncology 2004, Toronto, Canada
10. Chang J, Li X, Chang S, Berger M, Nelson S, **Cha S**. Anatomic distribution and extent of 1H MRSI metabolites in treatment-naive grade III and IV gliomas. International Society for Magnetic Resonance in Medicine 13th Scientific Meeting 2005, Miami, Florida
11. Chang J, Li X, Butowski N, Chang S, Prados M, Lamborn K, Berger MS, Nelson S, **Cha S**. Newly diagnosed glioblastoma multiforme: proton MR spectroscopic characteristics and correlation with clinical outcome. World Federation of Neuro Oncology and the American Society of Neuroradiology 2005, Edinburgh, Scotland
12. Yang L, Lupo J, Oh J, Mayo K, Chang J, Pelletier D, Nelson S, **Cha S**. Quantitative 3.0 Tesla Perfusion MRI of Deep Gray Matter in Multiple Sclerosis Patients: Correlation with Disease Status. International Society for Magnetic Resonance in Medicine 13th Scientific Meeting, 2005, Miami, Florida
13. Antonietti L, Mayo M, Lupo J, Dillon WP, Nelson S, Vandenberg S, **Cha S**. Perfusion, Diffusion, and Proton Spectroscopic MR Imaging of Low-grade Gliomas: Correlation with Histologic Subtypes. American Society of Neuroradiology 2005 Annual Meeting
14. Pirzkall A, Ozturk E, Choy R, Lupo J, Lee M, **Cha S**, Chang S, Berger M, Nelson S. MR based anatomic, metabolic and physiologic imaging information on spatial heterogeneity in newly diagnosed glioblastoma multiforme. International Society for Magnetic Resonance in Medicine 13th Scientific Meeting, 2005, Miami, Florida
15. Lee M, Lupo J, Xu D, Han E, **Cha S**, Chang S, Berger M, Vigneron D, Nelson S. Quantitative comparisons of spatial distortions in fast imaging using nonrigid registration. International Society for Magnetic Resonance in Medicine 13th Scientific Meeting, 2005, Miami, Florida

16. Mayo M, Chang J, Antonietti L, Li X, Butowski N, Dillon W, Nelson S, Vandenberg S, **Cha S**. Proton MRS And Perfusion MR Imaging Of Anaplastic Gliomas: Correlation With Histologic Subtypes. The American Society of Neuroradiology 43rd Annual Meeting, 2005, Toronto, Canada
17. **Cha S**, Martin A, Hoghooghi D, Weber O, Mayo M, Chang J, Dillon WP, Higashida R, Saloner D. International Society for Magnetic Resonance in Medicine 13th Scientific Meeting, 2005, Miami, Florida
18. Chang JS, Williams CK, Kornak J, McDermott MW, Berger MS, Vandenberg S, **Cha S**. Correlation of pMRI derived rCBV measurements and histopathologic analysis of tumor tissue from image-guided biopsy in patients with newly diagnosed glioblastoma multiforme. The American Society of Neuroradiology 44th Annual Meeting, 2006, San Diego, CA
19. Mayo M, Antonietti L, Kornak J, Kivette V, Chang S, **Cha S**. Perfusion MR Imaging of Glioblastoma Multiforme: Correlation with Survival. The American Society of Neuroradiology 44th Annual Meeting, 2006, San Diego, CA
20. Starkey, J., Tihan, T., **Cha, S**. Mimics of Brain Tumor at Neuroimaging with Clinicopathologic Correlation. The American Society of Neuroradiology 51st Annual Meeting, 2013, San Diego, CA
21. Villanueva-Meyer, J., Barajas, R., **Cha, S.**, Chen, W., Shankaranarayanan, A., Koon, P. P-33 - Feasibility of T1 Rho Mapping of Intracranial Tumors and Tumor-Related Edema. The American Society of Neuroradiology 51st Annual Meeting, 2013, San Diego, CA
22. Ali, S., Joseph, N. M., Perry, A., **Cha, S**. MR Imaging Diffusion Characteristics in Glioblastoma with Primitive Neuroectodermal Tumor-Like Components: An Uncommon Tumor Subtype. The American Society of Neuroradiology 51st Annual Meeting, 2013, San Diego, CA
23. Mabray, M, Starkey, J, Pekmezci, M, Perry, A, **Cha, S**, Susceptibility Imaging in Clinical Neuroradiology: The Key Sequence in an Expanding Group of Diseases. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013, Chicago IL.
24. Starkey, J, Tihan, T, **Cha, S**, It's Not a Tumor: How to Recognize Brain Tumor Mimics Using 5 MR Imaging Features. Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013, Chicago IL.
25. R Barajas¹, **S Cha**¹, M Mabray¹, J Rubenstein¹, F Valles¹, Dynamic Susceptibility-Weighted Perfusion Magnetic Resonance Imaging Metrics Are Predictive of Overall Survival in Patients with Recurrent Primary Central Nervous System Lymphoma. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada.
26. Starr, C, **Cha, S**, Dural-based Tumors and Mass-like Lesions: Five Imaging Clues to Diagnose Meningioma Mimics. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada.
27. M Mabray¹, K Kallianos¹, A Kansagra¹, **S Cha**¹, A Brain Tumor Mimic with a Characteristic Branching Vascular Abnormality on Susceptibility Imaging. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada.
28. M Mabray¹, J Villanueva-Meyer¹, A Kansagra¹, **S Cha**¹, Pattern-Based Approach to Pathology on Susceptibility Imaging. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada.

29. M Mabray¹, M Mamlouk¹, G Punch¹, C Glastonbury², **S Cha**¹, Infiltrating Gliomas Involving the Cranial Nerves: Case Series and Review of the Literature. The American Society of Neuroradiology 52nd Annual Meeting, Montreal, Canada.
30. Meyer,J, Mabray,M, **Cha,S**, Central Nervous System Vasculitis and Vasculopathy: Imaging Clues to Differentiate From Demyelinating Disease. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, November 30 - December 5, 2014, Chicago IL
31. Li,Y, Ali,S, Clarke,J, **Cha,S**, Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Complications. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, November 30 - December 5, 2014, Chicago IL.
32. Starr,C, Punch,G, Starkey,J, **Cha,S**, Dural-based Tumors and Mass-like Lesions: Five Imaging Clues to Diagnose Meningioma Mimics. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, November 30 - December 5, 2014, Chicago IL.
33. Barajas,R, Rubenstein,J, Mabray,M, Meyer,J, **Cha,S**, Combined Use of Apparent Diffusion Coefficient and Cerebral Spinal Fluid Biomarkers Improves Sensitivity and Specificity of Diagnosing Primary Central Nervous System Lymphoma. Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, November 30 - December 5, 2014, Chicago IL.